**Background**
Acute congestive heart failure (CHF) often occurs alongside renal impairment, creating a complex clinical challenge that requires targeted therapeutic intervention. In the cardiovascular and renal systems, adenosine receptors play a critical role in modulating blood flow and fluid balance. Specifically, the adenosine A1 receptor is a key target for managing these conditions. Beyond cardiovascular applications, recent research has highlighted the role of adenosine A1 receptors in the central nervous system. In neurodegenerative diseases, such as those induced by Tau protein pathology, neuronal dysfunction and hypometabolism are prevalent. Addressing these deficits is essential for restoring cognitive and motor functions. In this context, we will introduce a potent and selective adenosine A1 receptor antagonist – Rolofylline.
**Definition**
Rolofylline (also known as KW-3902) is a potent and selective adenosine A1 receptor antagonist. According to the Rolofylline description, this compound is utilized in the treatment of patients with acute congestive heart failure and renal impairment, as well as in the study of Tau-induced neurodegeneration.
**In Vitro and In Vivo Studies**
The pharmacological profile of Rolofylline is characterized by its metabolism via cytochrome P450 (CYP 450), which converts the parent compound into pharmacologically active M1-trans and M1-cis metabolites. When evaluating Rolofylline biological activity in the context of neurology, in vitro studies have demonstrated that the compound can alleviate presynaptic dysfunction. Specifically, it restores neuronal activity and increases dendritic spine levels, making it a promising candidate for combating the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases. Furthermore, research indicates that Rolofylline alleviates axonopathy caused by human Tau ΔK280. For researchers seeking detailed Rolofylline technical information, these findings suggest that the compound’s ability to modulate A1 receptors provides a neuroprotective effect against proteinopathies. In conclusion, Rolofylline is a selective adenosine A1 receptor antagonist with broad potential in both cardiovascular and neurodegenerative research.
Keywords
Rolofylline, 136199-02-5, KW-3902, KW3902, KW 3902, Adenosine Receptor, P1 receptor, Inhibitor, inhibitor, inhibit
References
[1] Stroh M, et al. Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. AAPS J. 2013 Apr;15(2):498-504.
[2] Dennissen FJ, et al. Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280. Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11597-11602. Epub 2016 Sep 26.